Formycon Reports Positive Phase III Data On Ustekinumab

Company Is Looking For Marketing Partner On Stelara Biosimilar By Year End

Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.

Formycon logo website magnifying glass
Formycon has celebrated the latest results for its FYB202 ustekinumab candidate • Source: Shutterstock

Formycon has become the latest company to report Phase III data for a Stelara (ustekinumab) rival, revealing positive preliminary efficacy and safety data from its “VESPUCCI” trial for its FYB202 proposed biosimilar version.

The study “demonstrates the comparable efficacy of FYB202 to the reference product Stelara in patients with moderate to severe psoriasis vulgaris (plaque psoriasis),” Formycon said, adding that this meant

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products